New academic drug screening platform for cancer treatment

Hoersholm, Denmark, November 7th, 2015 Oncology Venture has, in collaboration with Faculty of Health and Medical Sciences, University of Copenhagen, Faculty of Health, Århus University, Department of Oncology, Rigshospitalet, Copenhagen, Intomics, Copenhagen, Medical Prognosis Institute A/S, Hoersholm, Saniona AB, Copenhagen and Faculty of Health, University of Southern Denmark, Odense, published a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, announcing the establishment of a novel and unique cell line based drug screening platform for cancer treatment.

The consortium has initiated the establishment of DEN-50R, a novel and unique cell line based drug screening platform within cancer treatment. The NCI60 cell line panel is mostly derived from patients with no medical treatment. Over the years, the panel has been of significant value in contributing to the identification of new molecular mechanisms involved in cancer progression, and in creating new anti-cancer drugs. Early clinical trials of anti-cancer drugs most often recruit patients who have failed several different prior treatments. Therefore, there has been a need to develop a platform built on the concept underlying the NCI60 cell line panel, and extend it to allow testing of potential new drugs in the setting of drug resistance. For more information, please see attached poster.

“Our results with translating Drug Response Prediction from the NCI60 panel are very positive and the current academic project may add more value to this successful approach and we look forward to further collaboration” s ays Adjunct professor Peter Buhl Jensen, M.D., CEO of Oncology Venture.

For further information concerning Oncology Venture please contact:
Peter Buhl Jensen, CEO
Telephone: +45 21 60 89 22
E-mail: pbj@oncologyventure.com

About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. The business enterprise is based on “rescuing” anti-cancer drugs whose development has been interrupted in the clinical development stage. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 26 of the 32 clinical studies that were examined.

The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.